Sputnik V – The Lancet Report (2021) Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine

The Lancet Report: On Sputnik V has been published!

A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials. Here, we report preliminary results on the efficacy and safety of Gam-COVID-Vac from the interim analysis of this phase 3 trial.

Source: Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia – The Lancet

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext

TY – JOUR
T1 – Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
AU – Logunov, Denis Y
AU – Dolzhikova, Inna V
AU – Shcheblyakov, Dmitry V
AU – Tukhvatulin, Amir I
AU – Zubkova, Olga V
AU – Dzharullaeva, Alina S
AU – Kovyrshina, Anna V
AU – Lubenets, Nadezhda L
AU – Grousova, Daria M
AU – Erokhova, Alina S
AU – Botikov, Andrei G
AU – Izhaeva, Fatima M
AU – Popova, Olga
AU – Ozharovskaya, Tatiana A
AU – Esmagambetov, Ilias B
AU – Favorskaya, Irina A
AU – Zrelkin, Denis I
AU – Voronina, Daria V
AU – Shcherbinin, Dmitry N
AU – Semikhin, Alexander S
AU – Simakova, Yana V
AU – Tokarskaya, Elizaveta A
AU – Egorova, Daria A
AU – Shmarov, Maksim M
AU – Nikitenko, Natalia A
AU – Gushchin, Vladimir A
AU – Smolyarchuk, Elena A
AU – Zyryanov, Sergey K
AU – Borisevich, Sergei V
AU – Naroditsky, Boris S
AU – Gintsburg, Alexander L
N1 – doi: 10.1016/S0140-6736(21)00234-8
DO – 10.1016/S0140-6736(21)00234-8
T2 – The Lancet
JF – The Lancet
PB – Elsevier
N2 – BackgroundA heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials. Here, we report preliminary results on the efficacy and safety of Gam-COVID-Vac from the interim analysis of this phase 3 trial.
AB – BackgroundA heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials. Here, we report preliminary results on the efficacy and safety of Gam-COVID-Vac from the interim analysis of this phase 3 trial.
SN – 0140-6736
M3 – doi: 10.1016/S0140-6736(21)00234-8
UR – https://doi.org/10.1016/S0140-6736(21)00234-8
Y2 – 2021/02/02
ER –

Sputnik V: Lancet complete report PDF. PIIS0140673621002348

Now if you are like me, you read all this and just learned something today…

I call it, “Tidbit Time”!

WtR

kKEETON @ Windows to Russia…

Permission to reprint in whole or in part is gladly granted, provided full credit is given...